Full Member, McGill Centre for Translational Research in Cancer
Scientist, Department of Oncology, Research Institute, MUHC, Glen site
Dr. Abdulkarim's research focuses on the optimization of radiotherapy treatment delivery using advanced technology, the identification of surrogate blood-based biomarkers for radiation toxicity prediction, and the molecular characterization and mechanism of action of novel targeted therapies, such as combi-molecules in high grade glioma and triple negative breast cancer. On brain tumors, his research aims to investigate the role of MGMT in invasion/proliferation dichotomy. In breast cancer, the focus is on molecular subtyping triple negative breast cancer and developing a protein signature to predict the risk of locoregional relapse and distant metastasis. He is also working on a comprehensive program to study the effects of radiation on lung fibrosis, cancer invasion and metastasis. He is currently leading an active translational research program to develop new protocols for the treatment of cancer with combined modality ‘radiation and targeted agents', which includes both basic and clinical research.